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Abstract
 
Ligation of the Fas (CD95) receptor leads to an apoptotic death signal in T cells, B cells, and
 
macrophages. However, human CD34
 
1
 
–derived dendritic cells (DCs) and mouse DCs, re-
gardless of their maturation state, are not susceptible to Fas-induced cell death. This resistance
 
correlates with the constitutive expression of the Fas-associated death domain–like IL-1
 
b
 
–con-
verting enzyme (FLICE)-inhibitory protein (FLIP) ligand. We demonstrate a new role of Fas
in DC physiology. Engagement of Fas on immature DCs by Fas ligand (FasL) or by anti-Fas
antibodies induces the phenotypical and functional maturation of primary DCs. Fas-activated
DCs upregulate the expression of the major histocompatibility complex class II, B7, and DC–
lysosome-associated membrane protein (DC-LAMP) molecules and secrete proinflammatory
cytokines, in particular interleukin (IL)-1
 
b
 
 and tumor necrosis factor 
 
a
 
. Mature DCs, if ex-
posed to FasL, produce even higher amounts of IL-1
 
b
 
. Importantly, it is possible to reduce the
production of IL-1
 
b
 
 and interferon (IFN)-
 
g
 
 during DC–T cell interaction by blocking the
coupling of Fas–FasL with a Fas competitor. Finally, during cognate DC–T cell recognition,
IL-12 (p70) could not be detected at early or late time points, indicating that Fas-induced,
IFN-
 
g
 
 secretion is independent of IL-12.
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Introduction
 
The first step in any adaptive immune response is the acti-
vation of naive T cells in the LN. Once stimulated by in-
fection, dendritic cells (DCs) migrate to the draining LN
where naive T cells circulate and can encounter their spe-
cific antigen on the DC surface (1). Because this is a rare
event, the prolongation of cell survival and the correct acti-
vation state of DCs are of primary importance in order to
control and sustain the immune response.
We have previously reported that DCs express the Fas
receptor (CD95) (2), but its role on DCs is still a matter of
debate (3, 4). Stimulation of the Fas receptor normally in-
duces an apoptotic death signal. However, in T cells the in-
teractions between Fas and Fas ligand (FasL) do not always
induce a death signal (5). Indeed, depending on the state of
T cell activation, Fas–FasL interaction can also lead to T
cell activation and proliferation (6, 7). Thus, signaling
through Fas in the early stages of an immune response
might amplify the T cell response, whereas the signaling
through Fas could downsize the response via apoptosis of T
cells in later stages. Upon Fas activation and trimerization, a
set of effector proteins is recruited to this receptor, forming
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the death inducing signaling complex. Fas-associated death
domain (FADD), the first protein that binds to Fas, recruits
caspase-8, initiating a cascade of events resulting in efficient
cell death (8). Fas-induced apoptosis can be blocked by
FADD-like IL-1
 
b
 
–converting enzyme (FLICE)-inhibitory
proteins (FLIPs) (9). Furthermore, FLIP mediates the acti-
vation of nuclear factor 
 
k
 
B and extracellular signal–regu-
lated kinase (Erk), diverting Fas-mediated death signals into
signals that lead to proliferation and/or differentiation (10).
Both of these signaling pathways are activated by LPS and
play important roles in DC maturation and survival (11).
Recently, the disregulation of Fas–FasL interactions has
been considered as one of the major causes of exaggerated
immune responses, such as organ-specific autoimmune dis-
eases (12). In insulin-dependent diabetes mellitus, 
 
b
 
 islet
cells express Fas on their surface in response to IL-1
 
b
 
 and
become susceptible to Fas-induced cell death by activated
T cells (12).
In this study, we confirm that Fas is unable to induce DC
death due to a constitutive FLIP expression and further
demonstrate that FasL triggers both a phenotypical and
functional maturation of DCs, as well as the secretion of
proinflammatory cytokines, in particular IL-1
 
b
 
 and TNF-
 
a
 
.
 
Materials and Methods
 
Cells and Reagents.
 
Purification of human CD34
 
1
 
 cells, pri-
mary culture with FLT3-L, thrombopoietin, and stem cell factor,
and induction of DCs were performed as described previously
(13). Two growth factor–dependent DC mice lines, D1 and D8,
were used as well as bone marrow–derived fresh DCs (2, 14) and
were grown as described previously (2, 14). Bone marrow cells were
grown for 15–20 d and the homogeneity of the DC culture was
evaluated by cytofluorimetry. CD4
 
1
 
 T cells were purified from
TCR-OVA DO11.10 transgenic mice, bred in BALB/c back-
ground, by positive selection with an anti-CD4 antibody coupled
to magnetic microbeads, using MiniMacS Separating columns (all
from Miltenyi Biotec). LPS (
 
Escherichia coli
 
 serotype 026:B6) was
purchased from Sigma-Aldrich. FasL and anti-Flag Enhancer
were from Alexis, and Fas competitor (Fas-comp) was derived
as described (15). Human GM-CSF (Leucomax) was purchased
from Essex Chimie & Sandoz and used at 20 ng/ml. Other hu-
man cytokines were purchased from Peprotech and used at the
following concentrations: FLT3-L at 25 ng/ml, thrombopoietin
at 10 U/ml, stem cell factor at 20 ng/ml, IL-4 at 20 ng/ml (100
U/ml), and TNF at 40 ng/ml (200 U/ml).
 
Cell Stimulation, Antibodies, and Flow Cytometry Analysis.
 
Hu-
man DCs were incubated with TNF-
 
a
 
 (or anti-Flag Enhancer)
and FasL (Alexis) for 18–24 h at the indicated concentrations.
Cultured cells were stained with specific labeled mAbs or appro-
priate isotypic controls and incubated in 300 
 
m
 
l of saline, 3% FCS
containing 10 
 
m
 
g/ml of 7-amino-actinomycin D (7AAD; Sigma-
Aldrich) (16). Data were analyzed using WINMDI software by J.
Trotter (Scripps Institute, La Jolla, CA). For intracellular staining,
cells were incubated with mouse IgM anti-DC–lysosome-associ-
ated membrane protein (DC-LAMP, 10 
 
m
 
g/ml) for 30 min on
ice in the presence of permeabilization medium (0.3% saponin
and 2% BSA). Specific mouse anti–human mAbs were purchased:
anti-CD1a (clone OKT6) from Ortho Diagnostic Systems, anti–
HLA-DR (clone L243) from Becton Dickinson, anti-CD80
 
(clone BB1) and anti-CD86 (clone IT2.2) from BD PharMingen.
Anti–DC-LAMP antibody (clone 510 F1.65.13) was a gift of Dr.
S. Lebecque (Schering-Plough, Dardilly, France). Other reagents
used were as follows: polyclonal mouse IgG reagent grade from
Sigma-Aldrich and anti-CD34 mIgG-coated M450 Dynabeads
from Dynal. LPS-matured or nontreated murine DCs were cul-
tured either with anti-Flag Enhancer and FasL, anti-CD95 (Jo-2),
or an isotype-matched control, at the indicated concentrations.
After activation, cells were incubated with one of the following
mAbs from BD PharMingen: anti–(I-A
 
d
 
/I-E
 
d
 
) (2G9), anti-CD86
(B7.2), anti-CD95 (Jo-2), or hamster IgG (G235-2356). Staining
was carried out in the presence of 2-4G2 to block Fc receptor
binding. For each sample, culture supernatants were collected for
the cytokine production assay.
 
Cytokine Assays.
 
TNF-
 
a
 
, IL-1
 
b
 
, IL-10, and IFN-
 
g
 
 were
measured by using murine DuoSet™ following the manufac-
turer’s instructions (R&D Systems). IL-12 was tested using IL-12
capture (anti–IL-12 p70; 9A5) and detection (anti–IL-12 p40;
5C3). These antibodies and recombinant IL-12 were provided by
Dr. D.H. Presky (Hoffman-La Roche, Nutley, NJ). IL-2 was
tested by measuring [
 
3
 
H]thymidine incorporation of an IL-2–
dependent CTL clone (CTLL).
 
Assessment of apoptosis.
 
Apoptosis of DCs was assessed by flow
cytometry. For murine cells, the exposure of phosphatidylserine
residues on the cells’ surface was measured using FITC-conju-
gated annexin V (BD PharMingen) and dead cells were identified
with 1.25 
 
m
 
g/ml propidium iodide (Sigma-Aldrich). Alterna-
tively, human DCs were incubated on ice in 300 ml of saline, 3%
FCS containing 10 
 
m
 
g/ml of 7AAD (Sigma-Aldrich). Cells were
analyzed using FL-3 for 7AAD staining, which identified living
cells as 7AAD low, and dead and apoptotic cells as 7AAD high
and medium, respectively (16).
 
Antigen Presentation Assay.
 
D8 cells were seeded (10
 
4
 
 cells/
well) in flat-bottomed microtiter plates (Corning) pulsed with
CD4
 
1
 
 T cells (5 
 
3
 
 10
 
4
 
 cells/well) purified from TCR-OVA 
 
a
 
/
 
b
 
transgenic mice (T/DC, 5:1) in the presence of decreasing con-
centrations of peptide OVA 327–339 as indicated, with or with-
out 0.5 
 
m
 
g/ml of Fas-comp and in 0.3% normal mouse serum
supplemented with 100 IU/ml penicillin, 100 
 
m
 
g/ml streptomy-
cin, 2 mM 
 
L
 
-glutamine (all from Sigma-Aldrich), and 50 
 
m
 
M
2-mercaptoethanol. Proliferative responses were assessed 48 h
later by [
 
3
 
H]thymidine incorporation. Cell culture supernatants were
collected at the indicated times for cytokine production measures.
 
Western Blot Analysis of FLIP.
 
Human CD34-derived DCs
(5 
 
3
 
 10
 
5
 
) were lysed in 50 
 
m
 
l of lysis buffer (1% NP-40, 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, and Complete™ protease in-
hibitor cocktail tablets [Boehringer]). 30 
 
m
 
g of protein per lane
was subjected to electrophoresis under reducing conditions and
transferred to nitrocellulose (Hybond ECL; Amersham Pharmacia
Biotech). Blots were probed with anti-FLIP mAbs (Dave 2; Al-
exis), visualized using horseradish peroxidase–labeled, anti–rat
Abs (Southern Biotechnology Associates, Inc.), and ECL blotting
substrate (Amersham Pharmacia Biotech). Quantification on films
was performed using the ONE D-Scan program (Scanalytics) as
described previously (17).
 
Results
 
Fas Is Constitutively Expressed by DCs and Is Upregulated by
LPS or TNF-
 
a
 
.
 
Similar to mouse DCs (2), nonstimulated
immature, human CD34
 
1
 
–derived DCs were found to ex-
press Fas (Fig. 1 A). Therefore, we studied the regulation of
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Fas during maturation of human and mouse DCs induced
by TNF-
 
a
 
 or LPS. Incubation of human DCs with 40 ng/
ml of TNF-
 
a
 
 (Fig. 1 A) or LPS (data not shown) for 24 h
induced a slight upregulation of Fas. We next incubated a
well-defined, mouse spleen long-term growth factor–
dependent DC line (D1 cells) or primary murine bone
marrow–derived DCs (mBM-DCs) with LPS (10 
 
m
 
g/ml),
which induced a significant upregulation of Fas that was
more pronounced in primary mBM-DCs (compare Fig. 1,
B and C). Interestingly, incubation of agonistic anti-Fas an-
tibodies (Jo-2) resulted in a dose-dependent downregula-
tion of Fas (not shown) at early time points and in the up-
regulation of Fas at late time points (not shown).
 
DCs Are Resistant to Fas-induced Apoptotic Cell Death.
 
Since the induction of cell death by FasL remains contro-
versial (3, 4, 18), we have studied the effects of FasL or the
Jo-2 antibody on DCs. As shown in Fig. 2, A and B, both
human and mouse DCs were resistant to Fas-induced cell
death. Human CD34
 
1
 
–derived immature DCs or 72-h,
TNF-matured DCs (data not shown) were treated with
FasL and enhancer for 24 h and analyzed using 7AAD
 
staining (see Materials and Methods). No significant in-
crease of dead and apoptotic cells was noticed after FasL
treatment for 24 h in immature DCs (Fig. 2 A) or TNF-
matured DCs (data not shown). D1 cells and mBM-DCs,
pretreated or not with LPS for 20 h, were incubated with
different concentrations of anti-Fas antibody for 6 h. Cells
were double-stained with FITC-conjugated annexin V and
with propidium iodide. Cells single positive for annexin V
were considered as undergoing early apoptosis. As shown
in Fig. 2 B, regardless of the concentration of anti-Fas used,
a maximum 10% of the D1 cells underwent apoptosis
(when subtracting the amount of apoptotic cells after LPS
treatment), and no apoptosis was observed when anti-Fas
was tested on immature cells. Similar results were obtained
with fresh mBM-DCs (not shown). Finally, no significant
cell death occurred in mature or immature DCs during
cognate DC–T cell interaction (not shown).
 
DCs Constitutively Express FLIP.
 
Fas-induced apopto-
sis can be blocked during signal transduction by FLIPs (9).
We observed by Western blot analysis that FLIP was con-
stitutively expressed by human and mouse DCs. Further-
Figure 1. Surface levels of Fas (CD95) in immature
versus mature DCs. (A) Human CD341–derived DCs
were treated with 40 ng/ml of TNF-a for 24 h (solid
line) or left untreated (dashed line); isotype control
(gray line). Results are representative of three indepen-
dent experiments. (B) Mouse D1 cells or (C) mBM-
DCs were treated with 10 mg/ml LPS. Thick line,
treated cells; thin line, isotype control; dashed line, un-
treated cells (NT). Results are representative of four
experiments.
Figure 2. Fas does not induce apoptotic
cell death of immature or mature cells. (A)
Flow cytometry of human DCs treated with
FasL (right) or with boiled FasL (left) stained
with 7AAD (see Materials and Methods).
(B) Mouse DCs were either left untreated
or treated for 20 h with LPS only, with LPS
first and then with anti-Fas Jo-2 antibody
for an additional 6 h, or with anti-Fas Jo-2
antibody alone at the indicated concentra-
tions. Cells single positive for annexin
V–FITC are considered early apoptotic and
are plotted in the graph after subtracting the
percentage of untreated cells. (C) Western
blot for the expression of FLIPs in cell ex-
tracts of human DCs either untreated (NT)
or treated with TNF-a, with boiled FasL
(B.FasL), or with FasL (FasL) for 24 h. (D)
Quantitative measurements of relative FLIP
expression of C (based on four independent
experiments, 6SEM) as performed using
the ONE D-Scan program.
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Figure 3. Fas engagement triggers the phenotypical maturation of hu-
man and mouse DCs. (A) Surface expression of cellular receptors and in-
tracellular expression of DC-LAMP in human CD341–derived DCs
treated with 0.1 mg/ml FasL plus 0.5 mg/ml Enhancer for 24 h (black
line) versus 0.1 mg/ml boiled FasL plus 0.5 mg/ml Enhancer (gray line),
or isotype control mAbs (dotted gray line). Results are representative of
four independent experiments. (B) Comparison of B7.2 (CD86) upregu-
lation by LPS (left) or FasL plus Enhancer (right) in mouse D1 cells. (C)
Treatment of DCs (D1 cells, left; mBM-DCs, right) by anti-CD95 anti-
body (Jo-2) with concentrations ranging between 0.01 and 10 mg/ml or
an isotype control (thin line). Results are representative of three indepen-
dent experiments.
 
more, FLIP was upregulated approximately twofold at
24 h of DC incubation with FasL in human DCs (Fig. 2,
C and D). A similar upregulation of FLIP was observed
after FasL, TNF-
 
a
 
, or LPS treatment in either human or
mouse DCs (data not shown).
 
Fas Induces Phenotypical Maturation of DCs.
 
Subsequently,
we examined the potential role of FasL in DC maturation
(Fig. 3). Human (Fig. 3 A) and mouse (Fig. 3 B) DCs were
incubated for 18–24 h with 0.1 
 
m
 
g/ml FasL and with 0.5
 
m
 
g/ml of enhancer. This stimulus induced a strong upregu-
lation of maturation markers such as MHC class II, CD40,
CD80, CD83, and CD86 on the cell surface of human
CD34
 
1
 
–derived DCs as well as of intracellular DC-LAMP
(Fig. 3 A). The extent of maturation induced by FasL treat-
ment was comparable to that induced by TNF-
 
a
 
 or LPS
(data not shown). Moreover, human and mouse DCs could
be activated by FasL, but not by boiled FasL, excluding a
possible endotoxin contamination. The effect of FasL was
reproduced by the Jo-2 antibody. As shown in Fig. 3 C, as
low as 0.01 
 
m
 
g/ml of Jo-2 antibody was sufficient to induce
the maturation of both primary mBM-DCs and the D1 cell
 
line, whereas an isotype control for the Jo-2 antibody had
no effect (Fig. 3 C).
 
Fas Induces Functional Activation of Immature and Mature
DCs.
 
Cytokine secretion by DCs was tested in culture
supernatants after Fas engagement and was compared with
that induced by LPS (Fig. 4). Although the amount of
TNF-
 
a
 
 produced was comparable among LPS- and Fas-
matured DCs (Fig. 4 A), Fas-matured DCs secreted more
IL-1
 
b
 
 (Fig. 4 B). If LPS-matured DCs were subsequently
exposed to anti-Fas antibody, the production of IL-1
 
b
 
greatly increased (600 vs. 20 pg/ml with LPS alone, Fig. 4
B) as well as the amount of secreted IL-10 (Fig. 4 C). In
contrast, the amount of bioactive IL-12 (p70) secreted was
very low in Fas-matured DCs (Fig. 4 D). When we ana-
lyzed fresh mBM-DCs, similar results were obtained (Fig.
5, A and B).
 
Blocking Fas–FasL Interaction during Cognate DC–T Cell
Interaction Partly Inhibits the Production of IL-1
 
b
 
 and IFN-
 
g
 
.
 
To gain insight on the functional activation of DCs by
FasL, we measured cytokine production by DCs during
antigen-specific T cell proliferation in the presence or ab-
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sence of a Fas-comp (15). CD41 T cells were purified
from TCR-OVA DO11.10 mice and incubated with a ho-
mogenous mouse bone marrow–derived, long-term DC
line (D8; T/DC, 5:1) in the presence of varying concen-
trations of OVA 327–339 peptide, with or without 0.5
mg/ml Fas-comp. This concentration of competitor com-
pletely inhibited Fas-induced activation of DCs (not
shown). As shown in Fig. 6 A, T cell proliferation was not
reduced in the presence of Fas-comp; rather, an increase in
thymidine uptake was observed in the presence of Fas-
comp, probably because of a direct interaction with FasL
on T cells. Consistently, the amount of IL-2 produced in-
creased in the presence of Fas-comp. In contrast, DCs
were impaired in their capacity to secrete IL-1b, as shown
by the inhibition of cytokine released 48 h after DC–T cell
interaction in the presence of Fas-comp (Fig. 6 C). Al-
though the production of IL-2 by T cells was increased in
the presence of Fas-comp, the amount of IFN-g produced
was reduced (Fig. 6 D), suggesting an important role of
Fas–FasL interaction for the polarization of T cells. The re-
duced inhibition of IFN-g observed at 48 h of antigen pre-
sentation could result from a suboptimal amount of Fas-
comp when T cells are actively proliferating. Interestingly,
the production of IFN-g was not dependent on IL-12 se-
cretion because bioactive IL-12 (p70) could not be de-
tected in culture supernatants throughout the entire prolif-
erative response (Fig. 6 E).
Discussion
Unlike B cells and macrophages, which are susceptible to
Fas-induced cell death (19–21), DCs are largely resistant to
FasL. Although it has been reported that murine DCs un-
dergo apoptosis after cognate T cell interaction, partly me-
diated by Fas–FasL interaction (4), several studies have
shown that, in vivo, T cells induce survival of DCs (22),
and that in vitro, neither T cells nor FasL induce DC death
(3, 18). In this report, we confirm that DCs are resistant to
Figure 5. Fas-treated fresh mBM-DCs preac-
tivated with LPS produce large amounts of IL-
1b. Cytokine production was measured by
ELISA after 20 h of treatment with 10 mg/ml
LPS and then 6 h with anti-Fas at the indicated
concentrations (LPS1a-Fas 6 h); 20 h with 10
mg/ml LPS and then 6 h with isotype control, at
the indicated concentrations (LPS1Isot. 6h); 6 h
with anti-Fas (a-Fas 6h); 26 h with LPS alone
(LPS); or left untreated (NT). Results are repre-
sentative of three independent experiments.
Figure 4. Fas-matured D1 cells produce
large amounts of TNF-a and IL-1b. Cy-
tokine production was measured by ELISA
after 20 h incubation with anti-Fas antibody
at the concentrations indicated (a-Fas 20 h);
20 h with 10 mg/ml LPS and then 6 h with
anti-Fas (LPS1a-Fas); 26 h with anti-Fas
alone (a-Fas 26 h); 26 h with isotype con-
trol for Jo-2 antibody alone (Isotype 26 h);
26 h with LPS alone (LPS); or left untreated
(NT). Results are representative of three in-
dependent experiments.
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Fas-mediated cell death, irrespective of their maturation
stage. This resistance correlates with the constitutive expres-
sion in DCs of FLIP, an intracellular inhibitor of apoptotsis.
DCs have the unique capacity to prime T cells, and the
costimulatory surface molecules B7 and CD40 contribute
to this function (1). The counterpart of B7 on T cells,
CD28 for instance, increases the duration of TCR signal-
ing which correlates with T cell activation (23). A nonca-
nonical costimulatory molecule expressed on T cells is Fas.
The engagement of Fas on naive T cells, in suboptimal
stimulation via the TCR, induces the proliferation of T
cells (7, 24). Conversely, activated CTLs or Th1 cells ex-
press high levels of FasL (25); Fas–FasL interaction on T
cells has been proposed to promote the differentiation of
naive T cells into functional T cells (5, 10). In this report,
we demonstrate that the engagement of Fas on immature
DCs drives their phenotypical maturation and induces the
secretion of proinflammatory cytokines such as TNF-a and
IL-1b. Moreover, mature DCs exposed to anti-Fas pro-
duce increased amounts of IL-1b, indicating a different
outcome of Fas engagement of immature and mature DCs.
IL-1b was also produced during cognate DC–T cell inter-
action and its secretion was blocked with Fas-comp, indi-
cating a direct involvement of Fas–FasL for its production.
Since FLIP is constitutively expressed in DCs, and as a con-
sequence, caspase-8 and IL-1b–converting enzyme are in-
hibited, this IL-1b production is likely to be caspase-1 in-
dependent. This result concurs with recent data showing
that FasL induces caspase-1–independent IL-1b secretion
in peritoneal exudate cells (26).
Several reports have shown an important role of IL-1b
in the pathogenesis of organ-specific immunity. The expo-
sure of b islet cells to IL-1b induces a selective and func-
tional expression of Fas on b islet cells through the produc-
tion of nitrous oxide (27). Subsequently, Fas expressed on
b islet cells is recognized by FasL on activated T cells caus-
ing tissue destruction. Since mature DCs produce large
amounts of IL-1b in response to Fas–FasL interaction, we
can speculate that during a chronic inflammatory state, such
as in the case of organ-specific autoimmunity, mature DCs
recruited at the inflammation site are activated by FasL-
expressing T cells to produce IL-1b, which in turn can con-
tribute to the progression of the disease. A recent report, in
agreement with this hypothesis, shows that transgenic non-
obese diabetic mice expressing FasL in b cells are more
sensitive to diabetogenic T cells (28) in a FasL-dependant
manner. Since transgenic b cells were also expressing
higher amounts of Fas, it is possible that these cells, by ex-
pressing FasL, were directly activating DCs for IL-1b pro-
duction, which in turn would be responsible for Fas induc-
tion. Accordingly, transplantation of the fetal pancreas from
transgenic mice expressing murine CD95L on their b islet
cells under the kidney capsules of allogeneic animals re-
sulted in rapid graft rejection (29).
Though murine myeloid DCs did not secrete IL-12 after
Fas ligation, T cells did produce IFN-g in a Fas–FasL-
dependant manner. A Fas-comp did not affect T cell prolif-
eration and IL-2 production. Rather, an increased prolifer-
ation was observed, suggesting that Fas expressed on DCs
may have a dual role as both the activator of T cell prolifer-
ation and the director of T cell polarization into a Th1
phenotype, even in the absence of IL-12. Further experi-
ments on the effects of Fas–FasL interaction on T cells will
be needed to address this question.
Figure 6. IL-1b and IFN-g
release is partly inhibited by Fas-
comp during cognate DC–T cell
interaction. (A) DO11.10 Tg T
cell proliferative response to the
OVA 327–339 peptide in the
presence (r) or absence of 0.5
mg/ml Fas-comp (j). T cells
were incubated with or without
D8 cells, and T cell proliferation
was measured by [3H]thymidine
incorporation. (B) IL-2 level in
culture supernatants from the ex-
periment in A at 5 mg/ml of
peptide with Fas-comp (Fas-
comp, gray bars) or without Fas-
comp (ctrl, white bars) (0.5 mg/
ml). (C) IL-1b was greatly re-
duced in the presence of Fas-
comp at 48 h. (D) IFN-g secre-
tion was reduced in the presence
of Fas-comp at 24 h, and little
cytokine production was ob-
served in the absence of DCs
(CD41T). (E) IL-12 was almost
undetectable (,5 pg/ml) at all
analyzed time points, both with
and without Fas-comp. Results
are representative of three inde-
pendent experiments.
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Finally, our results demonstrate that Fas–FasL interaction
induces the maturation of DCs, the secretion of large
amounts of IL-1b by DCs, and drives the polarization of T
cells into a Th1 phenotype. These findings explain, at least
in part, the adverse effects obtained by the transgenic ex-
pression of FasL in transplanted organs (28, 29) and puts
clear constraints on the therapeutic use of FasL in autoim-
mune diseases.
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